Prognostic Factors For Outcome in Patients with Refractory and Relapsed Acute Lymphocytic Leukemia Treated with Inotuzumab Ozogamicin, a CD22 Monoclonal Antibody

BACKGROUND: Inotuzumab ozogamicin was found to be highly active in patients with refractory-relapsed acute lymphocytic leukemia (ALL), with an overall response rate of 58% and a median survival of 6.3 months. Identifying factors associated with different outcomes on inotuzumab therapy may help selec...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Hematol
Asıl Yazarlar: Jabbour, Elias, O’Brien, Susan, Huang, Xuelin, Thomas, Deborah, Rytting, Michael, Sasaki, Koji, Cortes, Jorge, Garcia-Manero, Guillermo, Kadia, Tapan, Ravandi, Farhad, Pierce, Sherry, Kantarjian, Hagop
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5505232/
https://ncbi.nlm.nih.gov/pubmed/25407953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23901
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller